Leadership Overview
Gilead Sciences has 10 executives leading key functions including corporate strategy, financial oversight, human resources, ethics, and supply chain management.
Committed to advancing transformative therapies for life-threatening diseases, Gilead Sciences focuses on discovering, developing, and commercializing innovative medicines to address significant unmet medical needs across global markets.
Committed to advancing transformative therapies for life-threatening diseases, Gilead Sciences focuses on discovering, developing, and commercializing innovative medicines to address significant unmet medical needs across global markets.
Leadership Roles at Gilead Sciences
Dustin Shung - Associate Director, Corporate Strategy and Projects, Chief Executive Officer Office At Gilead Sciences
Dustin Shung, the Associate Director, Corporate Strategy and Projects, Chief Executive Officer Office At Gilead Sciences, manages high-priority initiatives within the executive office. Shung coordinates cross-functional alignment to ensure corporate objectives remain synchronized with long-term biopharmaceutical goals. By analyzing market trends and internal performance metrics, the Associate Director facilitates informed decision-making for the executive leadership team. This role involves bridging communication gaps between departments to streamline project execution across the organization. Dustin Shung monitors the progress of strategic programs, ensuring that resource allocation matches the company's commitment to developing treatments for HIV/AIDS and viral hepatitis. Through rigorous project management and strategic planning, the Associate Director supports the overarching mission of delivering life-saving therapies to patients worldwide. The position requires constant collaboration with senior leadership to refine operational workflows and maintain the competitive edge of the firm in the global pharmaceutical landscape.
Amy Klug - Vice President, Chief of Staff, Corporate Strategy and Projects, Chief Executive Officer Office
Amy Klug, the Vice President, Chief of Staff, Corporate Strategy and Projects, Chief Executive Officer Office at Gilead Sciences, directs the operational cadence of the executive office. Klug synthesizes complex strategic data to provide actionable insights for the Chief Executive Officer. Overseeing the integration of corporate projects, the Vice President ensures that departmental goals align with the broader biopharmaceutical mission. This leadership role involves managing high-stakes communications and facilitating board-level discussions regarding oncology and antiviral research pipelines. Amy Klug optimizes internal processes to enhance organizational agility, allowing the company to respond rapidly to emerging medical needs. By fostering collaboration across diverse business units, the Chief of Staff drives efficiency in the development and commercialization of medicines. The Vice President maintains a focus on long-term growth, ensuring that strategic initiatives support the firm's position as a leader in the global healthcare sector.
Andrew Dickinson - Chief Financial Officer
Andrew Dickinson, the Chief Financial Officer at Gilead Sciences, manages the financial health and capital allocation strategies of the organization. Dickinson oversees global financial planning, reporting, and investor relations to ensure sustainable growth. By evaluating investment opportunities in research and development, the Chief Financial Officer supports the advancement of innovative therapies for viral hepatitis and oncology. This role involves maintaining fiscal discipline while funding critical collaboration agreements with partners like Arcus Biosciences and Merck. Andrew Dickinson directs the financial architecture that enables the company to scale operations across the United States, Europe, and international markets. Through rigorous risk assessment and capital management, the Chief Financial Officer ensures the firm possesses the resources necessary to address unmet medical needs. The position requires constant engagement with the Board to align financial performance with the long-term strategic vision of the company.
Christopher Iwata - Chief of Staff To the Executive Vice President of Human Resources
Christopher Iwata, the Chief of Staff To the Executive Vice President of Human Resources at Gilead Sciences, coordinates the strategic initiatives of the human resources division. Iwata manages the operational flow of talent management programs, ensuring that the workforce remains aligned with the company's mission to develop life-saving medicines. By facilitating communication between the Executive Vice President and various internal stakeholders, the Chief of Staff streamlines decision-making processes related to organizational culture and employee development. Christopher Iwata monitors the implementation of HR policies that support a global team dedicated to treating HIV/AIDS and other serious conditions. This role involves analyzing workforce data to improve engagement and retention across international operations. Through effective project management, the Chief of Staff ensures that human capital strategies directly contribute to the firm's ability to innovate and deliver high-quality pharmaceutical products to patients in need.
Courtney Desmond - Chief of Staff To Senior Vice President Chief Ethics and Compliance Officer
Courtney Desmond, the Chief of Staff To Senior Vice President Chief Ethics and Compliance Officer at Gilead Sciences, manages the operational framework for corporate integrity and regulatory adherence. Desmond oversees the coordination of compliance programs that govern the development and commercialization of medicines. By facilitating communication between the Chief Ethics and Compliance Officer and internal departments, the Chief of Staff ensures that all business activities meet rigorous legal and ethical standards. Courtney Desmond monitors the implementation of policies that protect the company's reputation while supporting the delivery of treatments for viral hepatitis and oncology. This role involves managing complex projects that address regulatory requirements across global markets. Through diligent oversight and strategic planning, the Chief of Staff ensures that the organization maintains its commitment to transparency and patient safety. The position requires constant collaboration with legal and operational teams to mitigate risks and uphold corporate values.
Naomi Bautista - Gain Chief of Staff (Gilead Asian Interest Network)
Naomi Bautista, the Gain Chief of Staff (Gilead Asian Interest Network) at Gilead Sciences, directs the strategic operations of the employee resource group. Bautista coordinates initiatives that promote diversity, equity, and inclusion within the organization. By aligning the network's goals with the company's broader mission, the Chief of Staff fosters an environment that supports innovation and professional growth. Naomi Bautista manages the planning and execution of programs that highlight the contributions of Asian employees to the biopharmaceutical field. This role involves collaborating with leadership to ensure that diverse perspectives inform the development of treatments for HIV/AIDS and other conditions. Through effective project management, the Chief of Staff drives engagement and strengthens the internal community. The position requires constant communication with members and executive sponsors to ensure that the network's activities remain impactful and relevant to the firm's global workforce.
Sonja Tong - Executive Director and Chief of Staff
Sonja Tong, the Executive Director and Chief of Staff at Gilead Sciences, manages the operational priorities of the executive leadership team. Tong coordinates cross-functional projects that support the company's research and commercialization efforts. By facilitating communication between senior executives and department heads, the Executive Director ensures that strategic objectives remain clear and actionable. Sonja Tong oversees the implementation of initiatives that enhance organizational efficiency and support the development of therapies for serious invasive fungal infections. This role involves managing the flow of information to the executive office, enabling rapid decision-making in a fast-paced pharmaceutical environment. Through rigorous project management, the Chief of Staff ensures that resources are directed toward the most critical medical needs. The position requires constant collaboration with internal teams to maintain alignment with the firm's mission of delivering transformative medicines to patients across the globe.
Susanna Stinson - Director, Research Chief of Staff and Strategic Projects
Susanna Stinson, the Director, Research Chief of Staff and Strategic Projects at Gilead Sciences, manages the operational cadence of the research and development division. Stinson coordinates the execution of strategic projects that drive the discovery of novel therapies. By facilitating communication between research teams and executive leadership, the Director ensures that the pipeline remains focused on high-impact medical needs. Susanna Stinson oversees the integration of research initiatives, including collaborations with partners like Arcellx and Assembly Biosciences. This role involves managing the allocation of resources to support the development of treatments for oncology and viral hepatitis. Through effective project management, the Director ensures that scientific breakthroughs translate into commercialized medicines. The position requires constant collaboration with scientists and business leaders to maintain the firm's position at the forefront of biopharmaceutical innovation and patient care.
Deborah Son - Chief Marketing Officer, Supply Chain
Deborah Son, the Chief Marketing Officer, Supply Chain at Gilead Sciences, manages the commercial strategy for the company's supply chain operations. Son directs the distribution and market access initiatives for key products like Biktarvy and Veklury. By optimizing the supply chain, the Chief Marketing Officer ensures that life-saving medicines reach patients in the United States, Europe, and international markets efficiently. Deborah Son analyzes market demand to align production schedules with the needs of healthcare providers and patients. This role involves collaborating with logistics and commercial teams to maintain a robust supply of treatments for HIV/AIDS and COVID-19. Through strategic planning and operational oversight, the Chief Marketing Officer supports the firm's mission of delivering high-quality pharmaceutical products. The position requires constant engagement with global partners to ensure the reliability and accessibility of the company's diverse therapeutic portfolio.
Erik Schroeppel - Chief Marketing Officer, Supply Chain & Manager
Erik Schroeppel, the Chief Marketing Officer, Supply Chain & Manager at Gilead Sciences, manages the tactical execution of supply chain marketing and inventory management. Schroeppel directs the efforts to ensure the availability of oncology and pulmonary arterial hypertension treatments across global regions. By overseeing the coordination between manufacturing and commercial distribution, the Chief Marketing Officer ensures that products like Trodelvy and Letairis meet patient demand. Erik Schroeppel analyzes inventory data to improve the efficiency of the supply chain and reduce potential disruptions. This role involves managing the operational aspects of product launches and lifecycle management to support the firm's commercial goals. Through effective project management and strategic oversight, the Chief Marketing Officer ensures that the company maintains a consistent supply of essential medicines. The position requires constant collaboration with internal stakeholders to optimize the delivery of therapies to healthcare systems worldwide.
Explore Leadership Teams in Manufacturing
Vertex Pharmaceuticals Incorporated is a biotechnology company that develops and commercializes medicines for serious diseases with significant unmet medical needs. Its portfolio includes therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. The company also advances research programs in kidney disease, type 1 diabetes, myotonic dystrophy, and other genetic disorders, serving patients through healthcare providers, specialty pharmacies, hospitals, and distributors worldwide.
Company Leadership AD
RS
WM
SH
Telix Pharmaceuticals is a global, commercial-stage biopharmaceutical company headquartered in North Melbourne, Australia, publicly listed on the Australian Securities Exchange and Nasdaq under the ticker TLX. The company specializes in the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, commonly referred to as theranostics, which use molecularly targeted radiation to both image and treat cancer. Telix's pipeline is focused on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma), and bone marrow conditioning. Its lead commercial product, Illuccix, is an approved PSMA-PET/CT imaging agent for prostate cancer with regulatory clearance from the FDA, Australia's TGA, and Health Canada.
Company Leadership KR
CB


Alexion is a global biopharmaceutical company focused on the discovery, development, and commercialization of medicines for severe and life-threatening rare disorders. The company was established in 1992 and is headquartered in Boston, Massachusetts.
Company Leadership
MO
MH

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan.
Company Leadership
CP
CO
BH